GlobeNewsWire · IMCR · October 15, 2026

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Get the app for more

Explore stock news, insights and company research.